Benralizumab reduces cough and/or dyspnea frequency and improves cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia
In a post-hoc analysis of the MIRACLE trial, benralizumab significantly increased the proportion of patients transitioning from frequent to non-frequent cough at Week 8 (54.0% vs 39.7%, p=0.0051) and improved cough-related SGRQ items earlier than placebo, with sustained benefits through Week 48. Similar improvements were seen for dyspnea frequency at Week 8 (64.2% vs 47.1%, p=0.0026) and Week 48 (75.5% vs 63.4%, p=0.0221). Benefits were more pronounced in patients with baseline blood eosinophil counts ≥300 cells/μL.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Benralizumab reduces cough and/or dyspnea frequency and improves cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Benralizumab reduces cough and/or dyspnea frequency and improves cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia
This conclusion is most relevant to: Patients aged 12-75 years with uncontrolled severe eosinophilic asthma in Asia, with baseline frequent cough (n=383) or frequent dyspnea (n=304).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia. (Therapeutic advances in respiratory disease, 2026) — In a post-hoc analysis of the MIRACLE trial, benralizumab significantly increased the proportion of patients transitioning from frequent to non-frequent cough at Week 8 (54.0% vs 39.7%, p=0.0051) and improved cough-related SGRQ items earlier than placebo, with sustained benefits through Week 48. Similar improvements were seen for dyspnea frequency at Week 8 (64.2% vs 47.1%, p=0.0026) and Week 48 (75.5% vs 63.4%, p=0.0221). Benefits were more pronounced in patients with baseline blood eosinophil counts ≥300 cells/μL.
How It Works
The proposed biological pathway:
- ▸Benralizumab binds to IL-5 receptor alpha on eosinophils
- ▸Induces rapid depletion of eosinophils via antibody-dependent cell-mediated cytotoxicity
- ▸Reduces eosinophilic inflammation in airways
- ▸Leads to reduced cough and dyspnea frequency and improved cough-specific HRQoL
Who Might Benefit
Evidence fit by population:
- ▸Patients aged 12-75 years with uncontrolled severe eosinophilic asthma in Asia, with baseline frequent cough (n=383) or frequent dyspnea (n=304)
Recommended Dose
N/A (standard benralizumab dosing, not specified in abstract)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Post-hoc exploratory analysis, not pre-specified
- ▸Cough and dyspnea measured via SGRQ items, not validated cough-specific clinical endpoints
- ▸No long-term safety or efficacy data beyond 48 weeks
- ▸Subgroup analyses may be underpowered
Frequently Asked Questions
How quickly does benralizumab reduce cough in severe eosinophilic asthma?▼
Benralizumab showed significant improvement in cough frequency by Week 8, with 54.0% of patients transitioning to non-frequent cough compared to 39.7% with placebo.
Does benralizumab improve dyspnea in severe eosinophilic asthma?▼
Yes, benralizumab significantly reduced dyspnea frequency compared to placebo at both Week 8 (64.2% vs 47.1%) and Week 48 (75.5% vs 63.4%).
Are the benefits of benralizumab on cough and dyspnea sustained over time?▼
Yes, improvements in cough-related SGRQ items were sustained through Week 48, and dyspnea improvements were also maintained at Week 48.
Which patients benefit most from benralizumab for cough and dyspnea?▼
Patients with higher baseline blood eosinophil counts (≥300 cells/μL) showed more pronounced benefits, likely reflecting a higher inflammatory burden.
References
- 1.Lai K, Sun D, Dai R, Xu X, Zhao J, Wu T, Ho CN, Werkström V, Cohen D, Necander S, Zhong N. “Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia..” Therapeutic advances in respiratory disease, 2026. PMID: 42661269 DOI: 10.1177/17534666261471304